Valiloxybate

Pharmaceutical compound From Wikipedia, the free encyclopedia

Valiloxybate (INNTooltip International Nonproprietary Name, USANTooltip United States Adopted Name;[2] developmental code name XW-10172) is an extended-release prodrug of γ-hydroxybutyrate (GHB; oxybate) which is under development for the treatment of narcolepsy.[1][3][4][5][6] It is also being investigated for treatment of excessive daytime sleepiness (EDS) in people with Parkinson's disease.[7] The drug is taken orally once per night.[1][4][5][8][6]

Other namesValiloxibic acid; Valiloxybic acid; 4-((L-Valyl)oxy)butanoic acid; XW-10172; XW10172; XWL-008; XWL008
Routes of
administrationOral[1]
Drug classGABAB receptor agonist; GHB receptor agonist; Hypnotic
ATC code
  • None
Quick facts Clinical data, Other names ...
Valiloxybate
Clinical data
Other namesValiloxibic acid; Valiloxybic acid; 4-((L-Valyl)oxy)butanoic acid; XW-10172; XW10172; XWL-008; XWL008
Routes of
administration		Oral[1]
Drug classGABAB receptor agonist; GHB receptor agonist; Hypnotic
ATC code
  • None
Identifiers
  • 4-[(2S)-2-amino-3-methylbutanoyl]oxybutanoic acid
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
Chemical and physical data
FormulaC9H17NO4
Molar mass203.238 g·mol−1
3D model (JSmol)
  • CC(C)[C@@H](C(=O)OCCCC(=O)O)N
  • InChI=1S/C9H17NO4/c1-6(2)8(10)9(13)14-5-3-4-7(11)12/h6,8H,3-5,10H2,1-2H3,(H,11,12)/t8-/m0/s1
  • Key:RMGPNQKZEPTAOC-QMMMGPOBSA-N
Close

Pharmacology

It is an amino acid (L-valine) ester prodrug of GHB,[6][2] which itself acts as a GABAB and GHB receptor agonist.[9][10] Relative to administration of GHB itself, valiloxybate showed a delayed time to peak levels and an extended duration of GHB exposure in humans.[6] It is said to maintain desired GHB levels for 6 to 7 hours.[11] This profile is compatible with once-nightly dosing,[6] in contrast to GHB itself which is typically administered twice per night due to its very short elimination half-life.[12][13][14] In addition, unlike sodium oxybate, valiloxybate contains no sodium or cation, and hence avoids excessive sodium intake.[6][15]

History

Valiloxybate is under development by XW labs or XWPharma.[1] As of September 2025, no recent development has been reported, but valiloxybate has reached phase 1 clinical trials for treatment of narcolepsy and phase 2 trials for treatment of sleeping problems in Parkinson's disease.[1][7]

See also

References

Related Articles

Wikiwand AI